NewEdge Advisors LLC Increases Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• NewEdge Advisors increased its IQVIA stake by 21.5% in the first quarter, holding 35,368 shares valued at approximately $6.03 million. Institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting adjusted EPS of $3.15 versus the $3.03 consensus and revenue of $4.37 billion, up 8.7% year over year. The company also authorized a $2 billion share buyback covering up to 6.8% of outstanding shares.
• Analyst sentiment remains favorable, with multiple firms raising price targets and the stock carrying a “Moderate Buy” consensus rating. However, insiders sold 12,913 shares worth about $3.10 million over the past 90 days.

NewEdge Advisors LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,368 shares of the medical research company's stock after acquiring an additional 6,252 shares during the quarter. NewEdge Advisors LLC's holdings in IQVIA were worth $6,032,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Apella Capital LLC increased its holdings in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company's stock worth $211,000 after purchasing an additional 58 shares during the period. Quadrant Capital Group LLC increased its position in shares of IQVIA by 1.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company's stock worth $1,080,000 after purchasing an additional 60 shares during the last quarter. Private Advisor Group LLC lifted its position in IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company's stock valued at $1,163,000 after purchasing an additional 63 shares during the last quarter. Keybank National Association OH increased its holdings in shares of IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company's stock worth $2,052,000 after buying an additional 67 shares during the last quarter. Finally, First Growth Capital LLC raised its position in shares of IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company's stock valued at $375,000 after buying an additional 68 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares of the company's stock, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company's stock, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 over the last 90 days. 1.70% of the stock is owned by corporate insiders.

IQVIA Trading Up 1.5%

NYSE IQV opened at $242.23 on Tuesday. The stock has a market cap of $39.87 billion, a P/E ratio of 30.05, a price-to-earnings-growth ratio of 2.03 and a beta of 1.18. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $251.36. The stock has a 50 day simple moving average of $202.03 and a two-hundred day simple moving average of $186.65. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm's revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. Royal Bank Of Canada raised their price target on IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Wall Street Zen raised shares of IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. William Blair raised shares of IQVIA to a "strong-buy" rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings upgraded shares of IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $241.88.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source